The examples discussed below relate generally to medical fluid delivery. More particularly, the examples disclose systems, methods and apparatuses for dialysis, such as hemodialysis (“HD”), hemofiltration (“HF”) hemodiafiltration (“HDF”) automated peritoneal dialysis (“APD”).
Due to various causes, a person's kidneys can fail. Renal failure produces several physiological derangements. It is no longer possible to balance water and minerals or to excrete daily metabolic load. Toxic end products of nitrogen metabolism (urea, creatinine, uric acid, and others) can accumulate in blood and tissue.
Kidney failure and reduced kidney function have been treated with dialysis. Dialysis removes waste, toxins and excess water from the body that normal functioning kidneys would otherwise remove. Dialysis treatment for replacement of kidney functions is critical to many people because the treatment is life saving.
One type of kidney failure therapy is Hemodialysis (“HD”), which in general uses diffusion to remove waste products from a patient's blood. A diffusive gradient occurs across the semi-permeable dialyzer between the blood and an electrolyte solution called dialysate to cause diffusion. Hemofiltration (“HF”) is an alternative renal replacement therapy that relies on a convective transport of toxins from patient's blood. This therapy is accomplished by adding substitution or replacement fluid to the extracorporeal circuit during treatment (typically ten to ninety liters of such fluid). That substitution fluid and the fluid accumulated by the patient in between treatments is ultrafiltered over the course of the HF treatment, providing a convective transport mechanism that is particularly beneficial in removing middle and large molecules (in hemodialysis there is a small amount of waste removed along with the fluid gained between dialysis sessions, however, the solute drag from the removal of that ultrafiltrate is not enough to provide convective clearance).
Hemodiafiltration (“HDF”) is a treatment modality that combines convective and diffusive clearances. HDF uses dialysate flowing through a dialyzer, similar to standard hemodialysis, to provide diffusive clearance. In addition, substitution solution is provided directly to the extracorporeal circuit, providing convective clearance.
Most HD (HF, HDF) treatments occur in centers. A trend towards home hemodialysis (“HHD”) exists today in part because HHD can be performed daily, offering therapeutic benefits over in-center hemodialysis treatments, which occur typically bi- or tri-weekly. Studies have shown that a patient receiving more frequent treatments removes more toxins and waste products than a patient receiving less frequent but perhaps longer treatments. Studies on HHD have shown a reduction in anti-hypertensive medications while restoring normotension. Randomized trials on long daily dialysis have shown a reduction in left ventricular hypertrophy, which is a surrogate marker for improved patient survival. In addition a patient receiving more frequent treatments does not experience as much of a down cycle as does an in-center patient who has built-up two or three days worth of toxins prior to a treatment, providing much better quality of life. In certain areas, the closest dialysis center can be many miles from the patient's home causing door-to-door treatment time to consume a large portion of the day. HHD can take place overnight or during the day while the patient relaxes, works or is otherwise productive.
Another type of kidney failure therapy is peritoneal dialysis, which infuses a dialysis solution, also called dialysate, into a patient's peritoneal cavity via a catheter. The dialysate contacts the peritoneal membrane of the peritoneal cavity. Waste, toxins and excess water pass from the patient's bloodstream, through the peritoneal membrane and into the dialysate due to diffusion and osmosis, i.e., an osmotic gradient occurs across the membrane. Osmotic agent in dialysis provides the osmotic gradient. The spent dialysate is drained from the patient, removing waste, toxins and excess water from the patient. This cycle is repeated.
There are various types of peritoneal dialysis therapies, including continuous ambulatory peritoneal dialysis (“CAPD”), automated peritoneal dialysis (“APD”), tidal flow dialysate and continuous flow peritoneal dialysis (“CFPD”). CAPD is a manual dialysis treatment. Here, the patient manually connects an implanted catheter to a drain to allow spent dialysate fluid to drain from the peritoneal cavity. The patient then connects the catheter to a bag of fresh dialysate to infuse fresh dialysate through the catheter and into the patient. The patient disconnects the catheter from the fresh dialysate bag and allows the dialysate to dwell within the peritoneal cavity, wherein the transfer of waste, toxins and excess water takes place. After a dwell period, the patient repeats the manual dialysis procedure, for example, four times per day, each treatment lasting about an hour. Manual peritoneal dialysis requires a significant amount of time and effort from the patient, leaving ample room for improvement.
Automated peritoneal dialysis (“APD”) is similar to CAPD in that the dialysis treatment includes drain, fill and dwell cycles. APD machines, however, perform the cycles automatically, typically while the patient sleeps. APD machines free patients from having to manually perform the treatment cycles and from having to transport supplies during the day. APD machines connect fluidly to an implanted catheter, to a source or bag of fresh dialysate and to a fluid drain. APD machines pump fresh dialysate from a dialysate source, through the catheter and into the patient's peritoneal cavity. APD machines also allow for the dialysate to dwell within the cavity and for the transfer of waste, toxins and excess water to take place. The source can include multiple sterile dialysate solution bags.
APD machines pump spent dialysate from the peritoneal cavity, though the catheter, and to the drain. As with the manual process, several drain, fill and dwell cycles occur during dialysis. A “last fill” occurs at the end of APD and remains in the peritoneal cavity of the patient until the next treatment.
In any of the above modalities, entrained air and other gases are a concern. Entrained air can cause inaccuracies when pumping dialysate for either PD or HD. Entrained air can cause a reduction in effective surface area in a hemodialysis filter when it accumulates on the filter fibers, leading to a reduction in the effectiveness of the therapy. Entrained air entering a patient's peritoneum during PD can cause discomfort. Entrained air entering a patient's bloodstream during HD can have severe consequences. Even though the patient may be protected from an air embolism in some HD equipment, there have been situations with removing the air from the blood in which the patient has had to throw away the extracorporeal circuit, resulting in blood loss and cost. Accordingly, a need exists to provide an apparatus that ensures that entrained air is removed from dialysate or blood prior to delivering such fluids to the patient.
The present disclosure may employ level sensing and coordinated pumping and valving algorithms to control the fluid level in an air trap. In addition, the present disclosure allows the system to flow either gas or fluid (saline and/or heparin and/or priming solution and/or dialysis solution and/or blood and/or etc.) out of a fluid circuit directly to a fluid drain and/or fluid vessel (i.e. saline bag and/or priming bag and/or dialysis solution bag and/or container). Also, the present disclosure allows the system to flow gas out of a fluid circuit directly to atmosphere and fluid (saline and/or heparin and/or priming solution and/or dialysis solution and/or blood and/or etc.) out of a fluid circuit directly to a fluid drain and/or fluid vessel (i.e. saline bag and/or priming bag and/or dialysis solution bag and/or container).
The method of controlling level and removing air described above has advantages in the areas of priming and air trap level control. Currently air trap level control is a manual process. Prior to the therapy, the operator must connect a port on the air trap to a luer connection on the instrument. This port connects the air trap to a compressor on the instrument. This in turn allows for lowering or raising the air trap fluid level through level control switches on the instrument. If the operator does not make this connection securely, blood can flow up through this port and into the instrument during the therapy placing the patient at risk for blood loss and/or blood contamination. In other devices the patient attaches a syringe to the extracorporeal circuit to try to draw air out of the circuit. Because of the pressurization of the circuit blood loss can occur if the tubing is not closed properly after withdrawing air and there is also the risk of blood contamination during the manual procedure. The present disclosure eliminates these risks because the level control mechanism does not require the operator to make any connections.
During prime, the operator must monitor the fluid level in the air trap and manually raise this level to remove air from the extracorporeal circuit. During therapy, the operator must continue to monitor the fluid level in the air trap. If the operator fails to properly maintain the fluid level and lets this level drop to where air is able to pass through the air trap the patient is at risk for an air embolism. The air trap level changes with changes in fluid pressure, making frequent monitoring of the fluid level in the air trap important. The present disclosure removes both of those failure causes by using automatic level sensing to determine when action needs to be taken to raise the level and uses pump and valve configurations to automatically purge the air.
In addition, the present disclosure allows the priming solution from the extracorporeal circuit to be dumped to the drain. Currently the priming solution is either returned to the patient or purged to a waste container. Each of these methods have risks. If the priming solution is returned to the patient, it may return harmful substances that were released from the disposable kit and/or dialyzer during the prime, to the patient. If the priming solution is sent to a waste container, there is a risk that the patient may lose a significant amount of blood if the operator does not stop the purge at the appropriate time. With the current method of sending prime solution to a waste container, the operator connects the arterial bloodline to the patient's arterial access site. The venous line remains disconnected while the instrument draws blood from the patient and displaces priming fluid from the venous line into a waste container or rinse bucket. If the operator fails to stop the blood pump and connect the venous line to the patient when blood reaches the end of the venous bloodline, significant blood loss may result.
It is accordingly an advantage to provide improved systems and methods for the removal of air from dialysis systems.
Additional features and advantages are described herein, and will be apparent from, the following Detailed Description and the figures.
The systems described herein include common components (unless otherwise stated), such as the following dialysate valves: V-AVD-P, which is a primary dialysate air vent valve; V-AVD-S, which is a secondary air vent valve; V-BI, which is a balance chamber or balance tube inlet valve; V-B1-FI, which is a balance chamber 1 fresh inlet valve; V-B1-FO, which is a balance 1 fresh outlet valve; V-B1-SI, which is a balance chamber 1 spent inlet valve; V-B1-SO, which is a balance chamber 1 spent outlet valve; V-B2-FI, which is a balance chamber 2 fresh inlet valve; V-B2-FO, which is a balance chamber 2 fresh outlet valve; V-DD, which is a dialysate drain valve; V-DR, which is a dialysate recirculation valve; V-DBY, which is a dialyzer bypass valve; V-DI-PRE, which is a dialysate/infusate predilution hemofiltration or hemodialfiltration valve; V-DI-VEN, which is a dialysate/infusate postdilution hemofiltration or hemodialfiltration valve; V-DI-FIL, which is a dialysate/infusate inlet to the filter, and V-AV, which is an airline vent valve.
Common blood valves (unless otherwise stated) include V-AVB-P, which is a primary blood vent valve; V-AVB-S, which is a secondary blood vent valve; V-SA, which is a saline to arterial side of blood circuit valve; V-SV, which is a saline to venous side of blood circuit valve; and V-H, which is a heparin valve.
The above valves are all volcano or cassette type valves in one embodiment (pneumatically or electromechanically actuated). The following valves can instead be pinch valves or clamps: V-DB1 through V-DB6, which open and close supply lines to solution bags 1 to 6, respectively; V-ALC, which is an arterial Line clamp (fail safe); and V-VLC, which is a venous line clamp (fail safe).
The systems each include temperature sensors, such as: T-DC, which is a dialysis solution preheat temperature sensor; and T-DH, which is a dialysis solution heated temperature. The systems each include pressure sensors, such as: P-DO, which senses a pressure of fluid leaving the dialyzer or filter; P-AL, which is an arterial line pressure sensor; P-VL, which is a venous line pressure sensor; P-PPB, which is a post blood pump pressure sensor.
The systems each include optical sensors, such as: for balance chamber 1, O-B1-T1, transmitter 1 transmits to O-B1-R1, receiver 1 for end of travel; O-B1-T2, transmitter 2 transmits to O-B1-R2, receiver 2 for end of travel; O-B1-T3, transmitter 3 transmits to O-B1-R3, receiver 3 for end of travel; O-B1-T4, transmitter 4 transmits to O-B1-R4, receiver 4 for end of travel. Balance chamber 2 has the same set of end of travel optical sensors. O-HT1 is a heparin transmitter that transmits to O-HR1, heparin receiver to look for heparin instead of blood.
The systems each include other sensors, such as: CS 1 to 12, which are capacitive sensors for sensing the presence and/or orientation of the solution bags. AD-AL, which is an arterial line, e.g., ultrasonic, air detector. AD-VL, which is a venous line, e.g., ultrasonic, air detector. AD-HL, which is a heparin line, e.g., ultrasonic, air detector. BSD-VL, which is a venous line blood/saline, e.g., optical, detector. L-ATD, which is a dialysate air trap level sensor. L-ATB, which is a blood air trap level sensor. BLD, which is an e.g., optical, blood leak detector. ADS-A, which is an arterial line access disconnection sensor. ADS-V, which is a venous line access disconnection sensor.
The systems also include a drain relief valve RV-Drain and check valves CK-ATB for blood air trap, CK-PRE for prefilter infusate and CK-VEN for venous infusate.
The systems also include a filter, F-VL, which is a venous line macro-aggregate filter and other components such as ATD, which is a dialysate air trap and ATB, which is an air trap for blood.
The above valves and sensing areas for the above sensors can be placed in one or more disposable pumping cassette. For example, the systems can employ dedicated blood and dialysate cassettes with integrated air traps. Suitable configurations for cassettes with air traps are disclosed in co-pending patent application Ser. No. 11/865,577, entitled “Dialysis Systems Having Air Traps With Internal Structures To Enhance Air Removal”; Ser. No. 11/865,583, entitled “Dialysis Systems Having Air Separation Chambers With Internal Structures To Enhance Air Removal”; Ser. No. 11/865,552, entitled “Dialysis System Having Air Separation Chambers With Internal Structures To Enhance Air Removal”; and 60/976,731, entitled “Fluid And Air Handling In Dialysis Circuit Air Removal System”, each filed on Oct. 1, 2007, assigned to the eventual assignee of the present disclosure, the entire contents of each of which are incorporated expressly herein by reference.
Referring now to the drawings and in particular to
The air purging method of system 10 determines in one embodiment when it is necessary to remove air from the air trap, e.g., via an automatic level sensor L-ATD or L-ATB associated with air trap ATD and ATB, respectively, or via operator intervention. System 10 begins the air removal process by establishing an appropriate flow path from air trap ATD or ATB. The flow path from air trap ATD to drain 12 will be via dialysate circuit 20. The flow path from air trap ATB to drain 12 will be via blood circuit 30. Once the relevant flow path is open, system 10 displaces air from the air trap ATD or ATB, generating a pressure in the air trap that is higher than the pressure of drain 12. System 10 continues to displace air from the air trap ATD or ATB until automatic level sensor L-ATD or L-ATB, respectively, senses that it is no longer necessary to do so. Or, an operator visually determines that enough air has been removed from system 10.
One example of purging air from blood circuit 30 to drain 12 is illustrated in
System 10 then begins running PUMP-Blood clockwise, while metering air through the air vent valves V-AVB-S and V-AVB-P. Air vent valves V-AVB-S and V-AVB-P alternate in a chamber-lock type manner First, vent valve V-AVB-P is opened allowing air to pressurize the line up to vent valve V-AVB-S. Then, the valve states are reversed, allowing pressurized air trapped between the vent valves V-AVB-S and V-AVB-P to be released to drain 12 via air vent line 14. One of the vent valves is thus closed at all times, and the valves alternate at a rate related to the rate of PUMP-Blood.
The extracorporeal circuit level detector L-ATB may be used in combination with a blood leak detector BLD (see
System 10 begins a blood prime process after extracorporeal circuit 30 has been primed with priming fluid (saline, heparin, dialysis solution etc.). For blood prime, system 10 assures that the patient has been connected to the system or accessed. First, system 10 communicates circuit 30 with patient 18 flow path. System 10 then flows blood from patient 18, through the circuit 30, including air trap ATB, to displace priming fluid out of system 10 to the fluid drain 12, until the extracorporeal circuit is sufficiently primed with blood, e.g., using a blood detector BLD and/or flow sensing and/or a recorded number of pump rotations sufficient to completely remove priming fluid and/or a total time spent pumping sufficient to completely purge circuit 30 of priming fluid.
At step 2 in
At step 3 in
At step 4 in
At step 5 in
Referring now to
Referring now to
It is also possible in the vent to drain system 10 embodiments to maximize fluid use efficiently by pumping dialysis solution to prime the extracorporeal circuit. Here, a suitable path of valves is opened to allow fresh dialysate pump DF to pump fresh dialysate into dialyzer 16, and through the hollow fiber membranes of the dialyzer, into extracorporeal circuit 30. In this manner, system 10 can remove air from circuit 30 to drain using dialysate instead of requiring an extra priming fluid, such as saline. The dialysate can then be replaced with blood as shown above, so that the dialysate volume is not delivered to the patient.
In another primary embodiment shown in
In the vent to atmosphere embodiment, system 110 determines when it is necessary to remove air from the extracorporeal or dialysate side air traps ATD and ATB via automatic level sensors L-ATD and L-ATB and/or operator intervention as discussed above. System 110 begins the air removal process by establishing an appropriate flow path from the air trap ATD or ATB to atmosphere. Once the flow path is open, system 110 displaces air from the relevant air trap ATB, generating a higher than atmospheric pressure in the associated air trap and/or generating a lower than air trap pressure in the atmosphere, e.g., drawing a vacuum on the air trap. System 110 continues to displace air from the air trap until it is no longer necessary to do so (as determined by automatic level sensors L-ATD or L-ATB and/or via operator intervention.
In one sequence, the extracorporeal circuit level detector L-ATB detects a low fluid level. System 110 stops PUMP-Blood and dialysis solution pumps DF and DS. System 110 closes venous patient line clamp V-VLC, saline valves V-SV and V-SA, heparin valve V-H, and extracorporeal air vent valves V-AVB-S, V-AVB-P and opens saline valve V-SA. System 110 then slowly runs PUMP-Blood clockwise (as oriented in
The extracorporeal circuit level detector L-ATB may be used in combination with a blood leak detector BLD (see
System 110 begins a blood prime process after extracorporeal circuit 30 has been primed with priming fluid (saline, heparin, dialysis solution etc.). For blood prime, system 110 assures that the patient has been connected to the system or accessed. First, system 110 communicates circuit 30 with patient 18. System 110 then flows blood from patient 18 through the circuit 30, including air trap ATB to displace priming fluid out of system 110 to the fluid drain 12 until the extracorporeal circuit is sufficiently primed with blood, e.g., using a blood detector BLD and/or flow sensing and/or a recorded number of pump rotations sufficient to completely remove priming fluid and/or a total time spent pumping sufficient to purge circuit 30 of priming fluid.
In step 1 at
In step 2 at
In step 3 at
In step 4 at
In step 5 at
In step 6 at
In step 7 at
In step 7 at
In step 8 at
During the therapy, if air gathers in the top of air trap ATB, valves V-AVB-P and V-AVB-S are alternately opened so that air is shuttled out of the air trap without allowing any blood to escape and vented through valve V-AV and the 0.2 micron vent filter.
Just like with
In an alternative vent air to atmosphere embodiment, to prime the extracorporeal circuit to a greater extent, a blood detector BLD (see
Referring again to
It is also possible in the vent to atmosphere system 110 to use dialysis solution to prime extracorporeal circuit 30 as discussed above with vent to drain system 10.
In a further alternative primary embodiment shown in
System 210 determines when it is necessary to remove air from air trap ATB and ATD (via e.g., automatic level sensors L-ATB and L-ATD and/or operator intervention). System 210 begins the air removal process to by establishing an appropriate flow path from the air trap (extracorporeal ATB, dialysate ATD) to the saline bag 36. Once the flow path is open, system 210 displaces air from the air trap ATB or ATD by generating a higher than saline bag pressure in the air trap ATB or ATD and/or generating a lower than air trap pressure in the saline bag 36. System 210 continues to displace air from the air trap ATB or ATD until it is no longer necessary to do so, for example as determined by automatic level sensors L-ATB or L-ATD and/or operator intervention.
System 210 then runs Pump-Blood clockwise, while metering air through the air vent valves V-AVB-S or V-AVB-P. Either valve V-AVB-S or V-AVB-P is closed at all times for safety. The valves alternate in a chamber lock manner, which can be cycled at a rate related to the blood pump rate. This action pushes air to saline bag 36.
The extracorporeal circuit level detector L-ATB may be used in combination with a blood leak detector BLD (see
The blood prime process of system 210 begins after the extracorporeal circuit has been primed with priming fluid (saline, heparin, dialysis solution etc.). Blood prime assumes that the patient's blood access has been connected to the system. First, system 210 establishes the appropriate flow paths accomplished with the illustrated (
In step 1 at
In step 2 at
In step 3 at
In step 4 at
In step 5 at
In step 6 at
Referring to
Referring again to
As with system 10 in
Referring to
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present subject matter and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
The present application is a continuation of U.S. application Ser. No. 14/446,609, entitled “Blood Treatment Air Purging Methods”, filed Jul. 30, 2014, which is a continuation of U.S. application Ser. No. 13/894,020, entitled “Fluid and Air Handling in Blood and Dialysis Circuits”, filed May 14, 2013, now U.S. Pat. No. 8,834,403, issued Sep. 16, 2014, which is a continuation of U.S. application Ser. No. 12/237,160, entitled “Fluid and Air Handling in Blood and Dialysis Circuits”, filed on Sep. 24, 2008, now U.S. Pat. No. 8,444,587, issued May 21, 2013, which claims priority to and the benefit of U.S. Provisional Patent Application Ser. No. 60/976,731, filed Oct. 1, 2007, entitled “Fluid And Air Handling In Dialysis Circuit Air Removal System”, the disclosure if each of which is incorporated herein by reference and relied upon.
Number | Name | Date | Kind |
---|---|---|---|
250868 | Abbott | Dec 1881 | A |
927476 | Barker | Jul 1909 | A |
1505050 | Lauritsen | Aug 1924 | A |
2292007 | Morgan | Aug 1942 | A |
3044236 | Bearden et al. | Jul 1962 | A |
3074645 | Main | Jan 1963 | A |
3095062 | Neely | Jun 1963 | A |
3229445 | Kraft | Jan 1966 | A |
3287885 | Sommer | Nov 1966 | A |
3295297 | Collins | Jan 1967 | A |
3342019 | Smythe | Sep 1967 | A |
3412760 | Franck | Nov 1968 | A |
3527572 | Urkiewicz | Sep 1970 | A |
3581464 | Bhuta et al. | Jun 1971 | A |
3598727 | Wilock | Aug 1971 | A |
3677710 | Hirsch | Jul 1972 | A |
3744492 | Leibinsohn | Jul 1973 | A |
3756234 | Kopp | Sep 1973 | A |
3769207 | Baer | Oct 1973 | A |
3771288 | Wisman et al. | Nov 1973 | A |
3795088 | Esmond | Mar 1974 | A |
3827561 | Serfass et al. | Aug 1974 | A |
3830234 | Kopp | Aug 1974 | A |
3834386 | Sisley | Sep 1974 | A |
3849071 | Kayser | Nov 1974 | A |
3908653 | Kettering | Sep 1975 | A |
3964479 | Boag et al. | Jun 1976 | A |
3976311 | Spendlove | Aug 1976 | A |
3985134 | Lissot et al. | Oct 1976 | A |
3996027 | Schnell et al. | Dec 1976 | A |
4031891 | Jess | Jun 1977 | A |
4038190 | Baudet et al. | Jul 1977 | A |
4047563 | Kurata | Sep 1977 | A |
4048995 | Mittleman | Sep 1977 | A |
4054522 | Pinkerton | Oct 1977 | A |
4061031 | Grimsrud | Dec 1977 | A |
4102655 | Jeffrey et al. | Jul 1978 | A |
4137160 | Ebing et al. | Jan 1979 | A |
4149860 | Kulik | Apr 1979 | A |
4151088 | Wolf, Jr. et al. | Apr 1979 | A |
4191182 | Popovich et al. | Mar 1980 | A |
4200095 | Reti | Apr 1980 | A |
4293413 | Schnell | Oct 1981 | A |
4304670 | Watanabe et al. | Dec 1981 | A |
4311137 | Gerard | Jan 1982 | A |
4325715 | Bowman et al. | Apr 1982 | A |
4332264 | Gortz | Jun 1982 | A |
4344777 | Siposs | Aug 1982 | A |
4345919 | Wilkinson et al. | Aug 1982 | A |
4345999 | Sigdell et al. | Aug 1982 | A |
4353368 | Slovak et al. | Oct 1982 | A |
4363641 | Finn, III | Dec 1982 | A |
4368118 | Siposs | Jan 1983 | A |
4427009 | Wells et al. | Jan 1984 | A |
4433971 | Lindsay et al. | Feb 1984 | A |
4464172 | Lichtenstein | Aug 1984 | A |
4486188 | Altshuler et al. | Dec 1984 | A |
4493705 | Gordon et al. | Jan 1985 | A |
4512163 | Wells et al. | Apr 1985 | A |
4531937 | Yates | Jul 1985 | A |
4568333 | Sawyer et al. | Feb 1986 | A |
4583981 | Urquhart et al. | Apr 1986 | A |
4586925 | Carlsson et al. | May 1986 | A |
4622032 | Katsura et al. | Nov 1986 | A |
4643713 | Viitala | Feb 1987 | A |
4643715 | Isono et al. | Feb 1987 | A |
4666598 | Heath et al. | May 1987 | A |
4681606 | Swan, Jr. et al. | Jul 1987 | A |
4722725 | Sawyer et al. | Feb 1988 | A |
4722731 | Vailancourt | Feb 1988 | A |
4734269 | Clarke et al. | Mar 1988 | A |
4806135 | Siposs | Feb 1989 | A |
4923612 | Trivett et al. | May 1990 | A |
4932987 | Molina | Jun 1990 | A |
4941875 | Brennan | Jul 1990 | A |
4946439 | Eggers | Aug 1990 | A |
D311061 | Vrana et al. | Oct 1990 | S |
4976685 | Block, Jr. | Dec 1990 | A |
4997464 | Kopf | Mar 1991 | A |
5047147 | Chevallet et al. | Sep 1991 | A |
5049492 | Sauer et al. | Sep 1991 | A |
5059173 | Sacco | Oct 1991 | A |
5061236 | Sutherland et al. | Oct 1991 | A |
5061365 | Utterberg | Oct 1991 | A |
5112480 | Hukasawa | May 1992 | A |
5167921 | Gordon | Dec 1992 | A |
5178763 | Delaunay | Jan 1993 | A |
5204000 | Steadman et al. | Apr 1993 | A |
5228889 | Cortial et al. | Jul 1993 | A |
5246560 | Nekoksa et al. | Sep 1993 | A |
5259961 | Eigendorf | Nov 1993 | A |
5268077 | Bubik et al. | Dec 1993 | A |
5328461 | Utterberg | Jul 1994 | A |
5336165 | Twardowski | Aug 1994 | A |
5356376 | Milijasevic et al. | Oct 1994 | A |
5358481 | Todd et al. | Oct 1994 | A |
5368555 | Sussman et al. | Nov 1994 | A |
5394732 | Johnson et al. | Mar 1995 | A |
5411705 | Thor et al. | May 1995 | A |
5421815 | Noguchi et al. | Jun 1995 | A |
5429595 | Wright, Jr. et al. | Jul 1995 | A |
5441636 | Chevallet et al. | Aug 1995 | A |
5468388 | Goddard et al. | Nov 1995 | A |
5484397 | Twardowski | Jan 1996 | A |
5489385 | Raabe et al. | Feb 1996 | A |
5490925 | Eigendorf | Feb 1996 | A |
5503801 | Brugger | Apr 1996 | A |
5509895 | Noguchi et al. | Apr 1996 | A |
5520640 | Utterberg | May 1996 | A |
5578070 | Utterberg | Nov 1996 | A |
5591251 | Brugger | Jan 1997 | A |
5605540 | Utterberg | Feb 1997 | A |
5637081 | Noguchi et al. | Jun 1997 | A |
5643205 | Utterberg | Jul 1997 | A |
5650071 | Brugger et al. | Jul 1997 | A |
5674199 | Brugger | Oct 1997 | A |
5681294 | Osborne et al. | Oct 1997 | A |
5683355 | Fini et al. | Nov 1997 | A |
5690831 | Kenley | Nov 1997 | A |
5702606 | Peter, Jr. et al. | Dec 1997 | A |
5725776 | Kenley et al. | Mar 1998 | A |
5730730 | Darling, Jr. | Mar 1998 | A |
5763266 | Palsson et al. | Jun 1998 | A |
5776091 | Brugger et al. | Jul 1998 | A |
5776345 | Truitt et al. | Jul 1998 | A |
5800597 | Perrotta et al. | Sep 1998 | A |
5830185 | Block, Jr. | Nov 1998 | A |
5849065 | Wojke | Dec 1998 | A |
5851202 | Carlsson | Dec 1998 | A |
5858239 | Kenley et al. | Jan 1999 | A |
5863421 | Peter, Jr. et al. | Jan 1999 | A |
5895368 | Utterberg | Apr 1999 | A |
5902476 | Twardowski | May 1999 | A |
5910252 | Truitt et al. | Jun 1999 | A |
5928889 | Bakich et al. | Jul 1999 | A |
5931990 | Andrews | Aug 1999 | A |
5932103 | Kenley et al. | Aug 1999 | A |
5948251 | Brugger | Sep 1999 | A |
5951870 | Utterberg | Sep 1999 | A |
5980741 | Schnell et al. | Nov 1999 | A |
5983947 | Utterberg | Nov 1999 | A |
5989318 | Schroll | Nov 1999 | A |
6010623 | Schnell et al. | Jan 2000 | A |
6019824 | Schnell | Feb 2000 | A |
6046806 | Thompson | Apr 2000 | A |
6051134 | Schnell et al. | Apr 2000 | A |
6053967 | Heilmann et al. | Apr 2000 | A |
6066111 | Brockhoff | May 2000 | A |
6071269 | Schnell et al. | Jun 2000 | A |
6117342 | Schnell et al. | Sep 2000 | A |
6132616 | Twardowski et al. | Oct 2000 | A |
6146536 | Twardowski | Nov 2000 | A |
6171484 | Schnell et al. | Jan 2001 | B1 |
6176903 | Wamsiedler | Jan 2001 | B1 |
6187198 | Utterberg | Feb 2001 | B1 |
6206954 | Schnell et al. | Mar 2001 | B1 |
6251167 | Berson | Jun 2001 | B1 |
6274034 | Nikaido et al. | Aug 2001 | B1 |
6312414 | Brockhoff et al. | Nov 2001 | B1 |
6331252 | El Sayyid et al. | Dec 2001 | B1 |
6344139 | Utterberg | Feb 2002 | B1 |
6357600 | Scagliarini | Mar 2002 | B1 |
6391541 | Petersen et al. | May 2002 | B1 |
6391638 | Shaaltiel | May 2002 | B1 |
6464878 | Utterberg | Oct 2002 | B2 |
6481455 | Gustafson et al. | Nov 2002 | B2 |
6491656 | Morris | Dec 2002 | B1 |
6514255 | Ferree | Feb 2003 | B1 |
6537356 | Soriano | Mar 2003 | B1 |
6551513 | Nikaido et al. | Apr 2003 | B2 |
6558340 | Traeger | May 2003 | B1 |
6561997 | Weitzel et al. | May 2003 | B1 |
6562107 | Purdom et al. | May 2003 | B2 |
6572576 | Brugger et al. | Jun 2003 | B2 |
6582604 | Nikaido et al. | Jun 2003 | B2 |
6595948 | Suzuki et al. | Jul 2003 | B2 |
6755801 | Utterberg et al. | Jun 2004 | B2 |
6827862 | Brockhoff et al. | Dec 2004 | B1 |
6830553 | Burbank et al. | Dec 2004 | B1 |
7040142 | Burbank | May 2006 | B2 |
7087033 | Brugger et al. | Aug 2006 | B2 |
7097690 | Usher et al. | Aug 2006 | B2 |
7169352 | Felt et al. | Jan 2007 | B1 |
7186342 | Pirazzoli et al. | Mar 2007 | B2 |
7214312 | Brugger et al. | May 2007 | B2 |
20010042441 | Purdom et al. | Nov 2001 | A1 |
20020007137 | Utterberg | Jan 2002 | A1 |
20040019313 | Childers et al. | Jan 2004 | A1 |
20050131332 | Kelly | Jun 2005 | A1 |
20060213835 | Nimura et al. | Sep 2006 | A1 |
20090101550 | Muller et al. | Apr 2009 | A1 |
Number | Date | Country |
---|---|---|
296007 | Jan 1954 | CH |
1806654 | May 1970 | DE |
3442744 | Jun 1986 | DE |
0 058 325 | Aug 1982 | EP |
0 106 026 | Apr 1984 | EP |
0 143 340 | Jun 1985 | EP |
0 318 993 | Jun 1989 | EP |
0 350 675 | Jan 1990 | EP |
0 501 144 | Jan 1992 | EP |
560368 | Sep 1993 | EP |
0 587 251 | Mar 1994 | EP |
720856 | Jul 1996 | EP |
560368 | Feb 1998 | EP |
826383 | Mar 1998 | EP |
826384 | Mar 1998 | EP |
720856 | Oct 2001 | EP |
826384 | Oct 2001 | EP |
0 776 222 | Apr 2003 | EP |
1323439 | Jul 2003 | EP |
1323439 | Aug 2003 | EP |
826383 | Aug 2004 | EP |
1 408 319 | Oct 1975 | GB |
1 554 810 | Oct 1979 | GB |
2 061 755 | May 1981 | GB |
2 212 739 | Aug 1989 | GB |
3026703 | Jul 1998 | GR |
9823353 | Jun 1998 | WO |
Entry |
---|
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2008/080166 dated Jan. 20, 2009. |
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2008/077668 dated Jan. 13, 2009. |
European Office Action dated Nov. 5, 2014 for related European Appln. No. 08850086.3 (3 pages). |
Number | Date | Country | |
---|---|---|---|
20180036472 A1 | Feb 2018 | US |
Number | Date | Country | |
---|---|---|---|
60976731 | Oct 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14446609 | Jul 2014 | US |
Child | 15789535 | US | |
Parent | 13894020 | May 2013 | US |
Child | 14446609 | US | |
Parent | 12237160 | Sep 2008 | US |
Child | 13894020 | US |